Orum Therapeutics' Power Play: New Board Hires Signal Clinical Acceleration

BOSTON & DAEJEON, South Korea – April 13, 2026 – Orum Therapeutics is making a clear statement of intent, bolstering its leadership with two industry heavyweights as it prepares to transition its novel cancer therapies from the laboratory to the clinic. The recent appointments of Dr. Maria Koehler, a veteran oncology clinician, and Geoff Meyerson, a life sciences dealmaker, to its Board of Directors signal a strategic pivot towards rapid clinical development and commercialization in the highly competitive field of degrader-antibody conjugates (DACs).

The move, approved at the company's Annual General Meeting on March 27, 2026, is being interpreted by industry watchers as a calculated step to harness deep clinical and transactional expertise, positioning the dual-headquartered biotech to capitalize on its promising technology platform.

A Strategic Infusion of Expertise

Orum's leadership has been vocal about the strategic importance of these appointments. “Maria and Geoff join Orum at an important point in the Company’s evolution,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “As we advance our next wave of DAC programs to the clinic and continue to broaden our payload capabilities, their perspectives will be highly valuable.”

Dr. Koehler brings more than two decades of formidable experience in oncology. Her track record includes steering critical cancer drugs through development, most notably her leadership role in the development of Pfizer’s blockbuster breast cancer drug, IBRANCE® (palbociclib). Her C-suite experience as Chief Medical Officer at both Repare Therapeutics and Bicycle Therapeutics provides Orum with invaluable, hands-on knowledge of navigating the complex pathways of clinical trials, regulatory submissions, and biomarker strategy. This expertise is precisely what a company on the cusp of clinical entry needs to de-risk its pipeline.

“Orum has built a compelling approach to targeted protein degradation by combining the precision of antibodies with the catalytic potential of degrader payloads,” said Dr. Koehler. “I look forward to supporting the team as it works to translate this science into meaningful new therapeutic options for patients.”

Complementing Dr. Koehler’s clinical acumen is Geoff Meyerson’s extensive background in company building and strategic transactions. As Co-founder and CEO of Locust Walk, a global life science transaction firm, Meyerson has a proven record of navigating the intricate world of biotech financing, partnerships, and M&A. This expertise will be critical as Orum seeks to forge new collaborations and maximize the value of its proprietary TPD²® platform.

“What stands out about Orum is that the company has established a differentiated position in DACs, with strong scientific foundations and multiple paths to value creation across its platform and pipeline,” commented Mr. Meyerson.

Powering the Next Wave of Cancer Killers

The excitement surrounding Orum is centered on its innovative Dual-Precision Targeted Protein Degradation (TPD²) approach. In simple terms, the company is developing a new class of cancer drugs that function like a two-stage guided missile. The first stage is an antibody, which precisely targets and locks onto cancer cells, ignoring healthy tissue. The second stage is a novel degrader payload, which, once delivered inside the cancer cell, hijacks the cell's own protein disposal machinery to seek out and destroy specific disease-causing proteins.

This technology has already produced significant results. In November 2023, Bristol Myers Squibb acquired Orum's first-in-class GSPT1 degrader program, now known as BMS-986497, in a deal worth up to $180 million. The therapy, aimed at acute myeloid leukemia (AML), is currently in Phase 1 clinical trials, providing powerful external validation of Orum's science and a source of potential milestone payments.

Now, the company is advancing its next lead candidate, ORM-1153, a CD123-targeting DAC also designed for AML. With promising preclinical data recently presented at the American Association for Cancer Research (AACR) Annual Meeting, Orum plans to file an Investigational New Drug (IND) application with regulators in the second half of 2026 to begin human trials. The versatility of Orum's platform was further highlighted by a 2024 deal with Vertex Pharmaceuticals, which licensed the TPD² technology for use in developing conditioning agents for gene editing, showcasing applications beyond oncology.

Navigating a Competitive and Promising Field

Orum operates in the red-hot targeted protein degradation (TPD) space, a market projected to grow from around $500 million in 2024 to several billion dollars within the next decade. The field is populated by pioneers like Arvinas and clinical-stage companies such as Kymera Therapeutics and Nurix Therapeutics, all racing to bring protein-degrading drugs to market.

While the competition is fierce, Orum’s DAC approach provides a key differentiator. Traditional small-molecule degraders, known as PROTACs or molecular glues, can sometimes face challenges with systemic toxicity or reaching the desired cells effectively. By attaching its degrader to a cell-targeting antibody, Orum aims to enhance potency, improve the safety profile, and create a more durable therapeutic effect, combining the strengths of both antibody-drug conjugates (ADCs) and protein degraders.

This next-generation strategy places Orum at the convergence of two of the most exciting modalities in modern drug development and gives it a unique story to tell investors and potential partners.

Building on a Foundation of Financial Strength

A bold clinical strategy requires significant capital. Orum appears well-positioned, having successfully gone public on South Korea's KOSDAQ exchange in February 2025. More significantly, in December 2025, the company secured approximately $100 million in a financing round that saw strong participation from both new and existing investors, including Weiss Asset Management and Korea Investment Partners.

With a reported cash position of over 143 billion Korean won (roughly $100 million) in late 2025, Orum has the financial runway to fund its near-term clinical ambitions for ORM-1153 and continue expanding its discovery platform. The addition of Dr. Koehler and Mr. Meyerson provides the strategic oversight needed to deploy that capital effectively, transforming promising science into approved medicines.